senti-202
senti-202: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Senti Biosciences, Inc. (SNTI) | Phase 1 |
Clinical Trials (1)
SENTI-202-101: A Phase 1, Multicenter, Open-Label Study of SENTI-202, a Selective Off-the-Shelf Logic Gated CAR NK Cell Therapy, in Subjects With CD33 and/or FLT3 Expressing Malignancies
Frequently asked questions
Who is developing senti-202?
senti-202 is being developed by Senti Biosciences, Inc..
How many clinical trials involve senti-202?
BioSniper tracks 1 clinical trial involving senti-202.
Get deeper analysis on senti-202
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis